NUZ-001

Product

Last mentioned: Feb 26, 2026

Timeline

  1. Interim Analysis

    Expected window for preliminary safety and biomarker data review by the trial committee.

  2. Dosing Initiation

    First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.

  3. Trial Selection

    NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.

Stories mentioning NUZ-001 1

clinical-trial Bullish

Neurizon Begins Dosing NUZ-001 in Landmark HEALEY ALS Platform Trial

Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.

2 sources